FMP

FMP

Enter

CWBR - CohBar, Inc.

Financial Summary of CohBar, Inc.(CWBR), CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mit

photo-url-https://financialmodelingprep.com/image-stock/CWBR.png

CohBar, Inc.

CWBR

NASDAQ

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.

0.88 USD

0.1199 (13.63%)

About

ceo

Dr. Pinchas Cohen Dean, M.D.

sector

Healthcare

industry

Biotechnology

website

https://www.cohbar.com

exchange

NASDAQ

Description

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 ...

CIK

0001522602

ISIN

US19249J3077

CUSIP

19249J109

Address

1455 Adams Drive

Phone

650 446 7888

Country

US

Employee

9

IPO Date

Dec 15, 2017

Summary

CIK

0001522602

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

19249J109

ISIN

US19249J3077

Country

US

Price

0.88

Beta

1.56

Volume Avg.

1.55k

Market Cap

2.56M

Shares

-

52-Week

0.51-3.59

DCF

2.04

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.2

P/B

-

Website

https://www.cohbar.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest CWBR News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep